Agentix TCAC FCF 5A

Que fait Agentix ? Agentix Corp, with ticker AGTX and ISIN US00848A1034, is a company based in Dana Point, United States. The company went public on August 5, 2015. Agentix Corp engages in the development and commercialization of novel therapeutics targeting metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its primary focus is on therapeutic agents for metabolic conditions including Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). The company's pipeline includes AGTX-2004 and AGTX-2003. AGTX-2004 is described as a peripherally-acting CB1 receptor antagonist that has shown efficacy in animal models for obesity and Type 2 diabetes mellitus. AGTX-2003 is a peripherally-acting CB1 receptor inverse agonist that has demonstrated effectiveness in animal models related to obesity and non-alcoholic fatty liver disease. The company is involved in developing synthetic agonists, inverse agonists, and antagonists that modulate the endocannabinoid system (ECS), which is recognized as a regulatory system governing metabolism. Agentix Corp has wholly owned subsidiaries, including GSL Healthcare, Inc., and Agentix Australia Pty Ltd. The company's website is https://agentixcorp.com/. Agentix est l'une des entreprises les plus populaires sur Eulerpool.